Hidden helpers in TB’s armor: two lipoproteins shape the bacterial shield

Mycobacterium tuberculosis (Mtb) kills more people than any other bacterial species, in large part because of a tough, unusual cell envelope that protects the bacterium from medicines and the immune system. R. Lissner and colleagues set out to probe a little-studied group of proteins in that envelope called lipoproteins. They focused on 79 conserved putative lipoproteins that Mtb shares with the related species M. marinum, reasoning that conserved proteins are likely to play important roles. To test each candidate, the team used the CRISPR1-Cas9 (Sth1Cas9) gene editing system adapted for Mycobacteria to introduce frameshift mutations one gene at a time, effectively breaking each lipoprotein gene and observing what happened. This systematic approach allowed the researchers to look for changes in how the bacteria respond to antibiotics and how they build the complex carbohydrate-rich layers of their envelope. By examining the consequences of disabling each lipoprotein, the study aimed to reveal which of these conserved proteins are essential helpers in assembling the cell’s protective outer structures.

Using targeted frameshift mutations in each conserved lipoprotein-coding gene, the researchers identified two mutants, lpqZ and fecB, that stood out because they showed increased susceptibility to all tested antibiotics, implicating these genes in maintaining envelope integrity. Although lpqZ and fecB have sequence similarities to periplasmic substrate binding proteins (SBPs), the team found that neither protein associates with any inner membrane transporter complex, which is the usual role for SBPs. Instead, co-immunoprecipitation experiments revealed new partnerships: LpqZ interacts with the enzyme AftA and FecB interacts with AftB. AftA and AftB are essential enzymes involved in synthesis of the major mycobacterial glycoconjugates arabinogalactan and lipoarabinomannan. Consistent with those interactions, the lpqZ and fecB mutants showed measurable alterations in both arabinogalactan and lipoarabinomannan, linking the lipoproteins to defects in glycoconjugate production. Together these methods and results support the idea that these SBP-like proteins have been repurposed to assist key enzymes in cell envelope biosynthesis.

The study uncovers a new role for so-called orphaned SBP-like lipoproteins in mycobacteria: instead of ferrying substrates to transporters, lpqZ and fecB appear to cooperate with essential arabinofuranosyltransferases AftA and AftB to help build critical glycoconjugates in the cell envelope. This neofunctionalization—where a protein evolves a new job—adds a layer of complexity to how Mtb constructs its defensive armor and points to previously unrecognized molecular interactions that preserve envelope integrity. Because disabling lpqZ or fecB makes the bacteria more vulnerable to antibiotics, these lipoproteins or their interactions with AftA and AftB could represent new vulnerabilities to exploit in drug development. The fact that these proteins are conserved between Mtb and M. marinum also provides opportunities to study their function in different experimental systems, speeding follow-up work. Overall, the findings shift attention to a set of lipoproteins that might be promising targets for weakening the mycobacterial cell envelope and improving treatment outcomes.